The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Lipid modification of GRN163, an N3′ → P5′ thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Specific Association of Human Telomerase Activity with Immortal Cells and Cancer
Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P. L. C., Coviello, G. M., Wright, W. E., Weinrich, S. L., & Shay, J. W. (1994) · Science · doi:10.1126/science.7605428 · Cited by 7,091 · cited 1×
“The TRAP assay was performed with the TRAP-eze Telomerase Detection kit (Serologicals/Invitrogen) and established protocols (Kim et al., 1994; Piatyszek et al., 1995; Wright et al., 1995).”
MethodSelf-citationInhibition of telomerase limits the growth of human cancer cells
Hahn, W. C., Stewart, S. A., Brooks, M. W., York, S. G., Eaton, E., Kurachi, A., Beijersbergen, R. L., Knoll, J. H. M., Meyerson, M., & Weinberg, R. A. (1999) · Nature Medicine · doi:10.1038/13495 · Cited by 1,030
Protection of mammalian telomeres
de Lange, T. (2002) · Oncogene · doi:10.1038/sj.onc.1205080 · Cited by 942 · cited 1×
“Maintenance of telomeres is essential for preventing critically short telomeres from being fused together or recognized as damaged DNA needing repair (de Lange, 2002).”
BackgroundHuman Telomerase and Its Regulation
Cong, Y.-S., Wright, W. E., & Shay, J. W. (2002) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.66.3.407-425.2002 · Cited by 898
Self-citationAbsence of cancer–associated changes in human fibroblasts immortalized with telomerase
Morales, C. P., Holt, S. E., Ouellette, M., Kaur, K. J., Yan, Y., Wilson, K. S., White, M. A., Wright, W. E., & Shay, J. W. (1999) · Nature Genetics · doi:10.1038/5063 · Cited by 803
Self-citationTelomere shortening and apoptosis in telomerase-inhibited human tumor cells
Zhang, X., Mar, V., Zhou, W., Harrington, L., & Robinson, M. O. (1999) · Genes & Development · doi:10.1101/gad.13.18.2388 · Cited by 698
Kim, N. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.13.2595 · Cited by 686
Herbert, B.-S., Pitts, A. E., Baker, S. I., Hamilton, S. E., Wright, W. E., Shay, J. W., & Corey, D. R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.25.14276 · Cited by 539 · cited 1×
“The inhibition of telomerase through a variety of mechanisms has been shown previously to lead to progressive telomere shortening and growth arrest or cell death due to the critically short telomeres (Hahn et al., 1999; Herbert et al., 1999, 2002; Zhang et al., 1999; Asai et al., 2003).”
BackgroundSelf-citationWright, W. E., Shay, J. W., & Piatyszek, M. A. (1995) · Nucleic Acids Research · doi:10.1093/nar/23.18.3794 · Cited by 475
Self-citationPiatyszek, M. A., Kim, N. W., Weinrich, S. L., Hiyama, K., Hiyama, E., Wright, W. E., & Shay, J. W. (1995) · Methods in Cell Science · doi:10.1007/bf00981880 · Cited by 384
Self-citationLetsinger, R. L., Zhang, G. R., Sun, D. K., Ikeuchi, T., & Sarin, P. S. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.17.6553 · Cited by 304
Agrawal, S., Goodchild, J., Civeira, M. P., Thornton, A. H., Sarin, P. S., & Zamecnik, P. C. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.19.7079 · Cited by 291
An Alternate Splicing Variant of the Human Telomerase Catalytic Subunit Inhibits Telomerase Activity
Yi, X., White, D. M., Aisner, D. L., Baur, J. A., Wright, W. E., & Shay, J. W. (2000) · Neoplasia · doi:10.1038/sj.neo.7900113 · Cited by 214
Self-citationWhite, L. K., Wright, W. E., & Shay, J. W. (2001) · Trends in Biotechnology · doi:10.1016/s0167-7799(00)01541-9 · Cited by 171
Self-citationShay, J. W., Tomlinson, G. E., Piatyszek, M. A., & Gollahon, L. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.1.425 · Cited by 145
Self-citationHolt, S. E., Norton, J. C., Wright, W. E., & Shay, J. W. (1996) · Methods in Cell Science · doi:10.1007/bf00132889 · Cited by 131
Self-citationOligonucleotide N3′→P5′ phosphoramidates as efficient telomerase inhibitors
Herbert, B., Pongracz, K., Shay, J. W., & Gryaznov, S. M. (2002) · Oncogene · doi:10.1038/sj.onc.1205064 · Cited by 131
Self-citationTelomerase Activity Does Not Always Imply Telomere Maintenance
Ouellette, M. M., Aisner, D. L., Savre‐Train, I., Wright, W. E., & Shay, J. W. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.0114 · Cited by 117
Self-citationWang, E. S., Wu, K., Chin, A. C., Chen‐Kiang, S., Pongracz, K., Gryaznov, S. M., & Moore, M. A. S. (2003) · Blood · doi:10.1182/blood-2003-02-0546 · Cited by 83
Self-citationAntitumor effects of specific telomerase inhibitor GRN163 in human glioblastoma xenografts
Ozawa, T., Gryaznov, S. M., Hu, L. J., Pongracz, K., Santos, R. A., Bollen, A. W., Lamborn, K. R., & Deen, D. F. (2004) · Neuro-Oncology · doi:10.1215/s1152851704000055 · Cited by 56
Self-citation
Cited by
Bennett, C. F., & Swayze, E. E. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105654 · Cited by 1,374
Telomerase and cancer therapeutics
Harley, C. B. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2275 · Cited by 728
Self-citationRoles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies
Jafri, M. A., Ansari, S. A., Alqahtani, M. H., & Shay, J. W. (2016) · Genome Medicine · doi:10.1186/s13073-016-0324-x · Cited by 716
Self-citationTargeting telomeres and telomerase
De Cian, A., Lacroix, L., Douarre, C., Temime-Smaali, N., Trentesaux, C., Riou, J.-F., & Mergny, J.-L. (2008) · Biochimie · doi:10.1016/j.biochi.2007.07.011 · Cited by 572
Chemotherapeutic Approaches for Targeting Cell Death Pathways
Ricci, M. S., & Zong, W.-X. (2006) · The Oncologist · doi:10.1634/theoncologist.11-4-342 · Cited by 515
Metadata
- Authors
- Herbert, B.-S., Gellert, G. C., Hochreiter, A., Pongracz, K., Wright, W. E., Zielinska, D., Chin, A. C., Harley, C. B., Shay, J. W., & Gryaznov, S. M.
- Venue
- Oncogene
- Published
- 2005-05-23
- Volume
- 24
- Issue
- 33
- Pages
- 5262-5268
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2103172804
- Cited by
- 268
- References
- 20
- FWCI
- 6.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.